PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 67 filers reported holding PROTAGONIST THERAPEUTICS INC in Q2 2019. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2020 | $164,000 | -2.4% | 23,303 | -2.5% | 0.09% | +335.0% |
| Q4 2019 | $168,000 | +33.3% | 23,900 | +136.6% | 0.02% | +233.3% |
| Q1 2019 | $126,000 | -80.2% | 10,100 | -89.3% | 0.01% | -86.4% |
| Q4 2018 | $636,000 | -55.5% | 94,600 | -31.8% | 0.04% | -46.3% |
| Q3 2018 | $1,428,000 | +53.7% | 138,800 | +0.4% | 0.08% | +51.9% |
| Q2 2018 | $929,000 | +32.5% | 138,300 | +69.3% | 0.05% | +20.0% |
| Q1 2018 | $701,000 | +56.8% | 81,700 | +280.0% | 0.04% | +87.5% |
| Q4 2017 | $447,000 | +10.9% | 21,500 | -31.7% | 0.02% | -4.0% |
| Q1 2017 | $403,000 | -41.8% | 31,500 | 0.0% | 0.02% | -56.1% |
| Q4 2016 | $692,000 | -22.2% | 31,500 | -25.2% | 0.06% | -20.8% |
| Q3 2016 | $889,000 | – | 42,100 | – | 0.07% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 2,449,183 | $84,864,191 | 21.18% |
| Cannon Global Investment Management, LLC | 69,900 | $2,422,035 | 11.28% |
| ADAR1 Capital Management, LLC | 1,603,932 | $55,576,244 | 10.49% |
| Checkpoint Capital L.P. | 355,000 | $12,300,750 | 7.42% |
| Fairmount Funds Management LLC | 931,890 | $32,289,989 | 3.65% |
| BVF INC/IL | 3,319,290 | $115,013,399 | 3.22% |
| RTW INVESTMENTS, LP | 5,286,404 | $183,173,899 | 2.84% |
| Kynam Capital Management, LP | 800,000 | $27,720,000 | 2.14% |
| 683 Capital Management, LLC | 604,449 | $20,944,158 | 1.58% |
| Birchview Capital, LP | 48,000 | $1,663,200 | 1.54% |